Skip to main content
. 2016 Jul 7;7(32):51922–51933. doi: 10.18632/oncotarget.10458

Figure 5. Analysis of cell migration, invasion and tumor sphere formation abilities after erlotinib alone, verteporfin alone and combination treatment with verteporfin and erlotinib in H1975 cells.

Figure 5

(A) Decrease in cell migration ability in H1975 cells after combination treatment (B) Decrease in cell invasion ability in H1975 cells after combination treatment (C) Quantitative analysis of transwell invasion assay result, indicating combination treatment decreased cell invasion ability in H1975 cells (***P < 0.001). (D) Decrease in tumor sphere formation ability in H1975 cells after verteporfin treatment alone, and after combined treatment with verteporfin and erlotinib. (E) Quantitative analysis shows verteporfin treatment alone or combination treatment decreased tumorsphere formation ability in H1975 cells (*P < 0.05, **P < 0.01).